MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from issuance ofequity, net of issuance...$105,065K Proceeds from exercise ofwarrants$2,289K Proceeds from issuance ofequity, net of issuance...$912K Proceeds from exercise ofstock options and...$139K Proceeds from maturitiesof marketable...$45,743K Proceeds from sales ofmarketable securities$10,958K Net cash provided byfinancing activities$108,405K Net cash provided byinvesting activities$56,083K Canceled cashflow$618K Net change in cash,cash equivalents and...$96,224K Canceled cashflow$68,264K Stock-based compensation$13,046K Depreciation andamortization$8,436K Non-cash operating leaseexpense$2,473K Other noncurrentassets-$571K Prepaid expenses andother current assets-$547K Accrued and othercurrent liabilities$532K Other-$423K Amortization (accretion) ofpremium (discount) on...$411K Other noncurrentliabilities$102K Purchases of property andequipment$618K Net cash used inoperating activities-$68,264K Canceled cashflow$26,541K Net loss-$90,597K Operating leaseliabilities-$2,778K Accounts payable-$1,430K
Cash Flow
source: myfinsight.com

Tenaya Therapeutics, Inc. (TNYA)

Tenaya Therapeutics, Inc. (TNYA)